The stereospecificity of rolipram inhibition of particulate cyclic AMP-specific phosphodiesterase (PDE IV) from guinea-pig eosinophils has been investigated. ( 
INTRODUCTION
Cyclic AMP-specific phosphodiesterase (PDE IV) is a widely distributed family of enzymes [1, 2] . Specific inhibitors of PDE IV, such as rolipram, exert a multiplicity of effects in the central nervous system (CNS) and in peripheral cells and tissues [1, 2] . Several studies [3] [4] [5] have demonstrated that rolipram is a relatively weak competitive inhibitor of PDE IV; however, whether such an interaction can account for all of its wideranging actions is doubtful. For example, a stereospecific highaffinity rolipram-binding site has been demonstrated in brain tissue and may be involved in the CNS actions of rolipram [6, 7] . Furthermore, certain peripheral actions of PDE inhibitors, such as bronchodilatation, are more closely correlated with their abilities to displace [3H]rolipram from brain membranes than with inhibition of PDE IV [8] .
The high-affinity rolipram-binding site in brain membranes appears to be associated with PDE IV [7] . Recently, a highaffinity rolipram-binding site similar to that in brain was demonstrated on the cloned human monocyte PDE IV expressed in yeast [9] . The potency order of compounds inhibiting enzyme activity and displacing [3H]rolipram binding is distinct. Furthermore, the affinity of rolipram for the high-affinity binding site is markedly stereospecific, with (-)-rolipram exhibiting > 20-fold greater potency than (+)-rolipram, whereas only a slight (3-fold) enantiomeric potency difference is observed for enzyme inhibition. The significance of the high-affinity rolipram-binding site in regulating enzyme The results indicate the presence of a partially concealed stereospecific site (Sr) on eosinophil PDE IV possibly similar to the highaffinity rolipram-binding site in brain through which rolipram can potently inhibit enzyme activity. This site, which apparently is not present on partially purified pig aortic PDE IV, is concealed in freshly prepared eosinophil membranes but is exposed by solubilization or V-GSH treatment and is important in regulating intracellular cyclic AMP accumulation in intact cells. be resolved [9] .
A tightly membrane-bound PDE IV is the predominant PDE isoform in guinea-pig peritoneal eosinophils [10] . Inhibition of the membrane-bound enzyme and stimulation of cyclic AMP accumulation by PDE inhibitors in intact cells are poorly correlated [10] ; however, a closer correlation exists between inhibition of the deoxycholate/NaCI-solubilized enzyme and stimulation of cyclic AMP accumulation [11] . Solubilization does not affect the inhibitory potencies of several non-selective inhibitors [dipyridamole, trequinsin, AH-21-132, 3-isobutyl-1-methylxanthine (IBMX)] but the IC50 values of selective PDE IV inhibitors (rolipram, denbufylline, Ro-20-1724) are decreased by at least 10-fold [11] . Exposure of the membrane-bound PDE IV to vanadate-glutathione complex (V-GSH) also increases the potencies of these selective PDE IV inhibitors but not of non-selective inhibitors [11] . It was proposed that, as well as the catalytic site (Sc), a biologically important high-affinity site for rolipram (Sr) exists on eosinophil PDE IV which is concealed in freshly prepared membranes and exposed by solubilization or V-GSH [11] .
To test this hypothesis further, we have investigated the stereospecificity of the action of rolipram on eosinophil PDE IV. The results show that rolipram stereospecificity for the enzyme is markedly increased by solubilization or exposure to V-GSH, indicating that Sr is a stereospecific site. Furthermore, Sr, which is probably important in regulating cyclic AMP accumulation in intact eosinophils, may be similar to the brain high-affinity rolipram-binding site. 
Solubllization of particulate PDE IV
The membrane-bound PDE IV was solubilized by homogenizing freshly prepared membranes with a Dounce homogenizer (ten strokes) in 4 ml of homogenization buffer containing deoxycholate (0.5 %) and NaCl (100 mM). The homogenate was centrifuged at 100000 g for 30 min; the supernatant containing the solubilized activity was removed and the pellet resuspended in an equal volume of homogenization buffer. PDE IV and protein were measured in the initial homogenate as well as the cytosolic and particulate fractions.
Partial purification of solubilized POE IV Solubilized PDE IV containing 2-4 mg of protein was diluted to 30 ml in column buffer (20 mM Tris/HCl, 2 mM MgCl2, 1 mM dithiothreitol, 20,M Tos-Lys-CH2Cl, 0-2% deoxycholate, pH 7.5). The eluate was applied to a DEAE-trisacryl column (0.7 cm x 1 cm) pre-equilibrated with column buffer. The column was washed with 10 ml of column buffer and PDE activities were eluted with a linear gradient of NaCl (0-0.5 M, 24 ml) in column buffer. The flow rate was 1 ml/min and 1 ml fractions were collected. Assays on the pooled peak fractions were performed immediately after elution from the column.
Partial purfflcation of pig aortic PDE IV
Aortas of freshly slaughtered pigs were clamped with artery forceps, excised, rinsed with water and placed in Hepes-buffered Krebs solution (118 mM NaCl, 4.7 mM KCl, 2.5 mM CaCl2, 1.6 mM MgSO4, 1.2 mM KH2PO4, 5.6 mM glucose, 2 mM Hepes, pH 7.4) for transport from the abattoir back to the laboratory. Within 2 h of removal, the aortas were placed on a plastic dissecting mat, any extraneous tissue was trimmed from the outside of the aorta and the artery was cut lengthwise through the thoracic arterial stumps. The artery was then pinned out with syringed needles and excess blood was removed by suction. The endothelial layer was removed by rubbing the intimal surface of the artery with a cotton swab. A criss-cross pattern was cut into the smooth muscle to a depth of 3-4 mm using a scalpel blade. The resulting rectangular strips of smooth muscle were then plucked from the aorta and washed (Krebs solution) and blotted dry. Then 25 g of the smooth muscle strips were cut finely with sharp scissors and homogenized using a Waring Blender (3 x 35 s bursts) in 50-100 ml of an ice-cold solution of 20 mM-Tris/HCl (pH 7.5), 2 mM MgCl2, 1 mM dithiothreitol, 5 mM EDTA and 1 mg/ml aprotinin. The homogenate was transferred to 50 ml centrifuge tubes and further homogenized on ice using an Ultra-Turrax homogenizer. The homogenate was centrifuged (3000 g, 5 min). After removal of the supernatant, the pellet was sonicated (4 x 10 s at 20 s intervals) in a small volume (25-50 ml) of homogenization buffer. The sonicate was then centrifuged (3000 g, 5 min), the pellet discarded and the supernatant pooled with that from the first centrifugation step. The pooled supernatants were centrifuged at high speed (100000 g, 1 h, 4°C). The resulting supernatant (75-150 ml) was filtered (0.45,um) and protein determined before application to a column (40 cm x 2.4 cm) of DEAE-trisacryl (IBF, Villeneuve La Garenne, France) pre-equilibrated with the same column buffer (without deoxycholate) as was used for partial purification of solubilized eosinophil PDE IV. The column was washed with 500-600 ml of column buffer, and PDE activities were eluted with two successive linear gradients of NaCl (0-200 mM, 400 ml and 200-300 mM, 200 Preparation of Na3VO4-GSH complex (V-GSH) Preparation of V-GSH was by the method of Souness et al. [15] .
Separation of the stereoenantlomers of rolipram
The stereoenantiomers of rolipram were separated as described by Schneider et al. [7] . RESULTS Effect of solubilization on the stereospecificity of rolipram inhibition of PDE IV As described previously [11] , deoxycholate (0.5 %) plus NaCl (100 mM) solubilized almost all (> 95%) of the PDE IV activity in guinea-pig eosinophil membranes, whereas less than 50 % of the total particulate proteins were liberated. Lineweaver-Burk plots (Figure 1) Figure 1 Lineweaver-Burk plots of the bound particulate (a) and solubilized (b) PDE IV activities In the absence and presence of V-GSH A suspension of eosinophil membranes in 2 ml (2 mg of protein/ml) of homogenization buffer was prepared. Of this, 1 ml was diluted 1:1 in homogenization buffer and 1 ml of homogenization buffer containing deoxycholate (1 %) and NaCI (200 mM) was added to the remainder. PDE 1V was solubilized as described in the Materials and methods section. PDE IV activity in equivalent volumes of the bound particulate (a) and solubilized (b) preparation was measured over a range of cyclic AMP concentratfons in the absence (0) and presence (@) of GSH (2.8 mM) plus Na3VO4 (1.4 mM), which were mixed together and added to the assay mixture immediately before enzyme addition. Substrate concentration and velocity (v) are expressed in ,&M and pmol/min per ml respectively. The apparent Km values were as follows:
particulate PDE, 1 ,uM and 6 ,uM; particulate PDE + V-GSH, 4 ,uM and 20 uM; solubilized PDE, 4 ,sM and 20 IM; solubilized PDE + V-GSH, 6 ,M and 20 aM. Effect of partial purffication of solubilized POE IV on the stereospecfflcity of rolipram As described previously [11] , solubilized PDE IV was eluted as a single peak from a DEAE-trisacryl column. The recovery of the enzyme was 150 %, indicating perhaps the presence of an endogenous inhibitor in the solubilized membrane preparation. As with the bound particulate PDE IV, but in contrast with the solubilized prechromatographed enzyme, pronounced nonlinear kinetics were displayed by the partially purified PDE IV (Km = 1 #uM and 5 /M) (Figure 3 ). nply slight rolipram stereospecificity was observed against the partially purified PDE IV compared with the prechromatographed Relationship between inhibition of eosinophil PDE IV, cyclic AMP accumulation in intact eosinophils and (±)-[3H]rolipram binding to brain membranes Although we were unable to measure specific [3H]rolipram binding to eosinophil membranes, a strong significant correlation was observed for potency of several compounds in inhibiting rolipram binding to brain membranes and solubilized (prechromatographed) PDE IV (r = 0.98, P < 0.001, n = 7) (Figure 6b ). Only a weak correlation existed between displacement of rolipram binding and inhibition of eosinophil-bound particulate PDE IV (r = 0.71, P < 0.01, n = 7), and no correlation with pig aortic PDE IV (r = 0.14, P= 0.76, n = 7) was observed. A highly significant correlation was observed between displacement of rolipram binding and elevation of eosinophil cyclic AMP levels (r = 0.98, P < 0.001, n = 6) (Figure 6a ).
Lack of stereospecificity of rolipram inhibition of pig aortic PDE IV DEAE-trisacryl chromatography of a 100000 g cytosolic fraction of pig aorta resolved four peaks of activity which, in order of elution, corresponded to cyclic GMP-specific PDE (PDE V) (Km 
DISCUSSION
Stereospecificity is a variable feature of the multifold actions of rolipram. In certain in vivo CNS models, (-)-rolipram is 15-fold more potent than (+ )-rolipram in antagonizing reserpineinduced hypothermia in mice or inducing head twitches in rats [6] . Stereospecificity is apparent in other in vivo CNS actions of rolipram [16] [17] [18] [19] . However, in in vitro and in vivo pulmonary models, only a slight enantiomeric potency difference (2-3-fold) is observed on inhibition of mediator release and smooth muscle relaxation, and the manifestation of this depends on the conditions employed [20] . Although rolipram is a relatively weak competitive inhibitor of PDE IV from various sources [3] [4] [5] [6, 7, 211 which is in agreement with the pharmacological tests for antidepressant activity. Furthermore, the therapeutic plasma concentrations of rolipram are 2-20 nM [22] which are much lower than its inhibitory potency against brain PDE IV. A stereospecific high-affinity rolipram-binding site similar to that in brain is coexpressed with the cloned human monocyte PDE IV expressed in yeast [9] . There is little correlation between the structure-activity relationships of a limited number of compounds in their abilities to inhibit human monocyte PDE IV activity and compete for [3H]rolipram binding [9] . We recently proposed the existence of a biologically important high-affinity site (Sr) distinct from the catalytic site (Sc) on eosinophil PDE IV at which rolipram can potently interact [11] . The [11] , suggests that the native PDE IV may resemble more closely the solubilized or V-GSH-activated enzymes than the untreated membrane-bound PDE IV. Whether intracellular substances exist within eosinophils which can influence PDE IV activity in a manner similar to V-GSH awaits further investigation.
The evidence for the existence of the putative Sr prompts speculation concerning its nature. Although we [3] [4] [5] . In agreement with these previous studies, rolipram was a relatively weak (IC50 approx. 2,M) inhibitor of pig aortic PDE IV. No stereospecificity was apparent in rolipram action on pig aortic PDE IV. Rolipram is a weak effector of aortic smooth muscle and in this tissue PDE III and PDE IV inhibitors exhibit synergistic effects on contractility [23] . Perhaps, in this system, rolipram acts purely as a competitive PDE IV inhibitor. Alternatively, in view of the altered properties of the eosinophil PDE IV induced by the treatments detailed above, the rigorous homogenization procedures and the subsequent chromatography may have destroyed Sr or completely eliminated its influence on catalytic activity.
In conclusion, the results suggest the existence of a stereospecific site on eosinophil PDE IV at which rolipram can interact with great potency. This putative site appears to be important in regulating the function of intact eosinophils and may be similar to the high-affinity rolipram-binding site in brain. The location of this site in relation to the catalytic site awaits further investigation.
